-
- Kang Chang Kyung
- Department of Internal Medicine, Seoul National University College of Medicine, Republic of Korea
-
- Kim Youngju
- Department of Biomedical Sciences, Seoul National University College of Medicine, Republic of Korea Department of Pharmacology, Seoul National University College of Medicine, Republic of Korea
-
- Jo Hyeon Jae
- Department of Internal Medicine, Seoul National University College of Medicine, Republic of Korea
-
- Lee Chan Mi
- Department of Internal Medicine, Seoul National University College of Medicine, Republic of Korea
-
- Kim Nam Joong
- Department of Internal Medicine, Seoul National University College of Medicine, Republic of Korea
-
- Lee Chang-Han
- Department of Biomedical Sciences, Seoul National University College of Medicine, Republic of Korea Department of Pharmacology, Seoul National University College of Medicine, Republic of Korea Wide River Institute of Immunology, Seoul National University, Republic of Korea Convergence Research Center for Dementia, Seoul National University Medical Research Center, Republic of Korea Cancer Research Institute, Seoul National University Medical Research Center, Republic of Korea
-
- Choe Pyoeng Gyun
- Department of Internal Medicine, Seoul National University College of Medicine, Republic of Korea
-
- Park Wan Beom
- Department of Internal Medicine, Seoul National University College of Medicine, Republic of Korea
-
- Oh Myoung-don
- Department of Internal Medicine, Seoul National University College of Medicine, Republic of Korea
抄録
<p>The accurate identification of individuals without prior infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is pivotal for seroepidemiological research and vaccine trials. Because of widespread COVID-19 vaccination, the anti-nucleocapsid antibody continues to serve as a valuable marker for individuals without a history of COVID-19. This study aimed to comprehensively assess anti-nucleocapsid antibody positivity using diverse commercial and in-house immunoassays among individuals who contracted COVID-19 more than 3 years ago. We enrolled 44 participants with laboratory-confirmed COVID-19 between January and May 2020 from Seoul National University Hospital and its community treatment centers. The results showed anti-nucleocapsid antibody positivities ranged from 45.5% to 87.9% depending upon the immunoassay used. The study highlights the importance of considering the limited anti-nucleocapsid antibody positivity in participants with a distant COVID-19 history in seroepidemiological or vaccine research.</p>
収録刊行物
-
- Japanese Journal of Infectious Diseases
-
Japanese Journal of Infectious Diseases advpub (0), 2024-04-30
国立感染症研究所